Doo-Sik Shin
Samsung
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Doo-Sik Shin.
Journal of Clinical Pharmacy and Therapeutics | 2017
Doo-Sik Shin; Y.S. Lee; Hyun-Su Kim; T. Körnicke; Rainard Fuhr
SB5 is a biosimilar to the reference adalimumab (ADL) currently in development. The primary study objective was to demonstrate pharmacokinetic (PK) equivalence of SB5 to European Union‐sourced adalimumab (EU‐ADL), and United States‐sourced adalimumab (US‐ADL) in healthy subjects. Safety, tolerability and immunogenicity were also assessed as secondary objectives.
Archive | 2006
Young-Kwon Yoon; Seong-Ha Park; Doo-Sik Shin
Archive | 2011
Doo-Sik Shin
Archive | 2008
Sung-Hoon Kim; Yong-gu Lee; Doo-Sik Shin; Yeon-Jun Lee
Archive | 2010
Kil-Soo Ko; Doo-Sik Shin
Archive | 2010
Doo-Sik Shin
Archive | 2010
Kil-Soo Ko; Doo-Sik Shin
Archive | 2005
Doo-Sik Shin; Young-Kwon Yoon
Archive | 2009
Hyun-Ho Yu; Doo-Sik Shin; Young-Kwon Yoon
Archive | 2011
Ja-Won Seo; Doo-Sik Shin